Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTGKNB4)

DTT Name Epidermal growth factor receptor (EGFR)
Synonyms Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB
Gene Name EGFR
DTT Type
Successful target
 [1]
Related Disease
Angina pectoris [ICD-11: BA40]
Breast cancer [ICD-11: 2C60-2C6Y]
Colorectal cancer [ICD-11: 2B91]
Diabetic foot ulcer [ICD-11: BD54]
Ischemia [ICD-11: 8B10-8B11]
Lung cancer [ICD-11: 2C25]
Renal cell carcinoma [ICD-11: 2C90]
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Unspecific body region injury [ICD-11: ND56]
BioChemical Class
Kinase
UniProt ID
EGFR_HUMAN
TTD ID
T59328
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.10.1
Sequence
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA
Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity).
KEGG Pathway
MAPK signaling pathway (hsa04010 )
ErbB signaling pathway (hsa04012 )
Ras signaling pathway (hsa04014 )
Rap1 signaling pathway (hsa04015 )
Calcium signaling pathway (hsa04020 )
Cytokine-cytokine receptor interaction (hsa04060 )
HIF-1 signaling pathway (hsa04066 )
FoxO signaling pathway (hsa04068 )
Endocytosis (hsa04144 )
PI3K-Akt signaling pathway (hsa04151 )
Dorso-ventral axis formation (hsa04320 )
Focal adhesion (hsa04510 )
Adherens junction (hsa04520 )
Gap junction (hsa04540 )
Regulation of actin cytoskeleton (hsa04810 )
GnRH signaling pathway (hsa04912 )
Estrogen signaling pathway (hsa04915 )
Oxytocin signaling pathway (hsa04921 )
Epithelial cell signaling in Helicobacter pylori infection (hsa05120 )
Hepatitis C (hsa05160 )
Pathways in cancer (hsa05200 )
Proteoglycans in cancer (hsa05205 )
MicroRNAs in cancer (hsa05206 )
Pancreatic cancer (hsa05212 )
Endometrial cancer (hsa05213 )
Glioma (hsa05214 )
Prostate cancer (hsa05215 )
Melanoma (hsa05218 )
Bladder cancer (hsa05219 )
Non-small cell lung cancer (hsa05223 )
Central carbon metabolism in cancer (hsa05230 )
Choline metabolism in cancer (hsa05231 )
Reactome Pathway
SHC1 events in ERBB2 signaling (R-HSA-1250196 )
PLCG1 events in ERBB2 signaling (R-HSA-1251932 )
PIP3 activates AKT signaling (R-HSA-1257604 )
GRB2 events in EGFR signaling (R-HSA-179812 )
GAB1 signalosome (R-HSA-180292 )
SHC1 events in EGFR signaling (R-HSA-180336 )
EGFR downregulation (R-HSA-182971 )
GRB2 events in ERBB2 signaling (R-HSA-1963640 )
PI3K events in ERBB2 signaling (R-HSA-1963642 )
EGFR Transactivation by Gastrin (R-HSA-2179392 )
Constitutive Signaling by Aberrant PI3K in Cancer (R-HSA-2219530 )
Constitutive Signaling by EGFRvIII (R-HSA-5637810 )
RAF/MAP kinase cascade (R-HSA-5673001 )
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants (R-HSA-1236382 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
18 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [2]
Cetuximab DMLNCE0 Colorectal cancer 2B91.Z Approved [1], [3], [4]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [5]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [5]
Erlotinib DMCMBHA Non-small-cell lung cancer 2C25.Y Approved [6]
Gefitinib DM15F0X Solid tumour/cancer 2A00-2F9Z Approved [7], [8]
HEGF DMN0S1G Diabetic foot ulcer BD54 Approved [9]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [10], [11]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [12]
Necitumumab DMKOJSN Colorectal cancer 2B91.Z Approved [13]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [14]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [9]
Osimertinib DMRJLAT Non-small-cell lung cancer 2C25.Y Approved [15]
Panitumumab DMQPD1F Colorectal cancer 2B91.Z Approved [16]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [17]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [18]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [19], [20]
Icotinib hydrochloride DM5GFIK Non-small-cell lung cancer 2C25.Y Registered [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Approved Drug(s)
64 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Almonertinib DMCHA27 Non-small-cell lung cancer 2C25.Y Phase 3 [22]
Amivantamab DMZ7AMY Non-small-cell lung cancer 2C25.Y Phase 3 [23]
ASP1929 DMR71ST Head and neck cancer 2D42 Phase 3 [24]
Bevacizumab + Erlotinib DM0MI81 Metastatic colorectal cancer 2B91 Phase 3 [25]
CO-1686 DMWZ2TU Lung cancer 2C25.0 Phase 3 [26]
DE-766 DM0GUV2 Gastric adenocarcinoma 2B72 Phase 3 [5]
EGF816 DMCMJRA Non-small-cell lung cancer 2C25.Y Phase 3 [27]
HKI-272 DM6QOVN Breast cancer 2C60-2C65 Phase 3 [28]
Rindopepimut DMP6IMQ Brain cancer 2A00 Phase 3 [13]
SYM-004 DMOVEDH Metastatic colorectal cancer 2B91 Phase 3 [29]
Zalutumumab DM52QEZ Head and neck cancer 2D42 Phase 3 [5]
Indium-111 DMC3794 Solid tumour/cancer 2A00-2F9Z Phase 2/3 [30]
Varlitinib DMDG8Q3 Metastatic biliary tract neoplasms 2C14-2C17 Phase 2/3 [31]
ABT-414 DMGUTPN Glioblastoma multiforme 2A00.0 Phase 2 [32]
ABX-EGF DM91U0R N. A. N. A. Phase 2 [33]
ASP8273 DMHLXUY Non-small-cell lung cancer 2C25.Y Phase 2 [34]
BMS-599626 DMDPQV5 Solid tumour/cancer 2A00-2F9Z Phase 2 [35], [19]
BMS-690514 DMX302C Chronic pain MG30 Phase 2 [36]
CetuGEX DMAWKSM Solid tumour/cancer 2A00-2F9Z Phase 2 [37]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [19]
Depatuxizumab DM7GPMB Glioblastoma of brain 2A00.00 Phase 2 [38]
HER1-VSSP vaccine DMX6B95 Solid tumour/cancer 2A00-2F9Z Phase 2 [39]
HM-78136B DMZ3BER HER2-positive breast cancer 2C60-2C65 Phase 2 [40], [41]
Matuzumab DM2458E Gastric adenocarcinoma 2B72 Phase 2 [42]
MEHD-7945A DMHOF7T Colorectal cancer 2B91.Z Phase 2 [31], [43]
Pazopanib + Tyverb/Tykerb DMVJD2W Inflammatory breast cancer 2C62 Phase 2 [12]
Pelitinib DMIW453 Lymphoma 2A80-2A86 Phase 2 [44]
RM-1929 DMVU1R9 Head and neck cancer 2D42 Phase 2 [40]
Tarloxotinib DMA7ISF Non-small-cell lung cancer 2C25.Y Phase 2 [45]
TT-100 DMZE6Y9 Non-small-cell lung cancer 2C25.Y Phase 2 [46]
VATALANIB DMY0UEQ Solid tumour/cancer 2A00-2F9Z Phase 2 [28]
AFM24 DMFTZX0 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [47]
BDTX-189 DMODTX5 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [48]
CART-EGFR DM3I267 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [49]
EGFR CART DMDWCOF Colorectal cancer 2B91.Z Phase 1/2 [50]
EMB-01 DMCAUKW Neoplasm 2A00-2F9Z Phase 1/2 [51]
EMD 55900 DMMD10S Glioma 2A00.0 Phase 1/2 [33]
SN-32793 DMEJT5Z Non-small-cell lung cancer 2C25.Y Phase 1/2 [5]
Sym013 DMZM6I2 Epithelial ovarian cancer 2B5D Phase 1/2 [38], [40]
Sym015 DM9B7Z5 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [38]
ZN-e4 DMLV4U1 Non-small-cell lung cancer 2C25.Y Phase 1/2 [52]
S-222611 DMQGH76 Malignant solid tumour 2C10-2F32 Phase 1b [53]
AMG 595 DMJFKW3 Glioblastoma multiforme 2A00.0 Phase 1 [54]
Anti-EGFR CAR T DMIVUX1 Glioma 2A00.0 Phase 1 [55]
Anti-HER3/EGFR DAF DMDMNJ6 Metastatic epithelial tumour 2D60 Phase 1 [56]
AP32788 DMGDARN Non-small-cell lung cancer 2C25.Y Phase 1 [40]
AST-1306 DMD83WO Solid tumour/cancer 2A00-2F9Z Phase 1 [57], [58], [59]
BCA101 DMM0VBU Solid tumour/cancer 2A00-2F9Z Phase 1 [60]
BIBX-1382 DM79XGM Chronic lymphocytic leukaemia 2A82.0 Phase 1 [61]
Cipatinib DMJLNEF Solid tumour/cancer 2A00-2F9Z Phase 1 [31]
CLN-081 DM05R4C Non-small-cell lung cancer 2C25.Y Phase 1 [62]
CUDC-101 DM9ZOMD Solid tumour/cancer 2A00-2F9Z Phase 1 [63]
D2C7 DMIMK84 Glioblastoma of brain 2A00.00 Phase 1 [64]
EGFR806-specific CAR T cell DM3AD65 Atypical teratoid/rhabdoid tumour 2A00.1Y Phase 1 [65]
HER-2/HER-1 vaccine DMXETUQ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
IMGN289 DMT9MHE Solid tumour/cancer 2A00-2F9Z Phase 1 [66]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [67]
LY3164530 DM9RTXM Advanced cancer 2A00-2F9Z Phase 1 [43]
MCLA-158 DMF0O3X Solid tumour/cancer 2A00-2F9Z Phase 1 [68]
MM-151 DMXQHZC Solid tumour/cancer 2A00-2F9Z Phase 1 [38]
MR1-1 DME7JFM Brain cancer 2A00 Phase 1 [69]
PF-05230907 DM7GSZL Nontraumatic intracerebral hemorrhage 8B00.4 Phase 1 [70]
SI-B001 DMDSFEB Metastatic epithelial tumour 2D60 Phase 1 [71]
SYN004 DM0EZ69 Solid tumour/cancer 2A00-2F9Z Phase 1 [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 64 Clinical Trial Drug(s)
1 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrrolo[2,3-d]pyrimidine derivative 24 DMZQF9R N. A. N. A. Patented [72]
------------------------------------------------------------------------------------
9 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PKI166 DMSQ794 Esophageal cancer 2B70 Discontinued in Phase 2 [73]
RG7160 DM5KJGB Metastatic colorectal cancer 2B91 Discontinued in Phase 2 [74]
AZD4769 DMA3OWI Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [20]
PD-153035 DM7KJTI Psoriasis vulgaris EA90 Discontinued in Phase 1 [75]
TAK165 DMBE5OF Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [19]
AZD-9935 DMFE3CD Solid tumour/cancer 2A00-2F9Z Terminated [78]
CGP-52411 DMIWUFC Solid tumour/cancer 2A00-2F9Z Terminated [79]
CGP-53353 DM9VDZP N. A. N. A. Terminated [80]
Heparin-EGF-like factor DMMXG2I Gastrointestinal disease DE2Z Terminated [81], [82]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Discontinued Drug(s)
2 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
111In-hEGF DM9TQDE Breast cancer 2C60-2C65 Preclinical [76]
EGFR/IGFR tandem adnectin DMZ3YP6 Solid tumour/cancer 2A00-2F9Z Preclinical [77]
------------------------------------------------------------------------------------
103 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine DMHLF2S Discovery agent N.A. Investigative [83]
(3-Bromo-phenyl)-quinazolin-4-yl-amine DMMIPZ8 Discovery agent N.A. Investigative [84]
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin DM81JRF Discovery agent N.A. Investigative [85]
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate DMA43NY Discovery agent N.A. Investigative [86]
10-hydroxy-18-methoxybetaenone DM4R7X8 Discovery agent N.A. Investigative [87]
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile DM4BFHR Discovery agent N.A. Investigative [88]
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile DMTC5Y9 Discovery agent N.A. Investigative [88]
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile DMO97FR Discovery agent N.A. Investigative [86]
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide DMCN6PY Discovery agent N.A. Investigative [86]
2-methoxy-4-(2-nitrovinyl)phenol DMEAVD2 Discovery agent N.A. Investigative [86]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [89]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [89]
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one DMD4O6V Discovery agent N.A. Investigative [90]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [89]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [89]
3-Pyridin-4-yl-quinoline-6,7-diol DME1TUK Discovery agent N.A. Investigative [91]
4-(2-nitroprop-1-enyl)benzene-1,2-diol DMCHTI0 Discovery agent N.A. Investigative [86]
4-(2-nitrovinyl)benzene-1,2-diol DM62ZRE Discovery agent N.A. Investigative [86]
4-(2-nitrovinyl)phenol DMPTVR2 Discovery agent N.A. Investigative [86]
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline DMNBLQ8 Discovery agent N.A. Investigative [92]
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline DMK6JV7 Discovery agent N.A. Investigative [92]
4-(3-Bromo-phenylamino)-quinazoline-6,7-diol DM1Q5KV Discovery agent N.A. Investigative [84]
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid DMWBVMH Discovery agent N.A. Investigative [86]
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline DMLSGU1 Discovery agent N.A. Investigative [93]
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide DMN2TMS Discovery agent N.A. Investigative [94]
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline DMYUL9J Discovery agent N.A. Investigative [95]
4557W DMLE0I7 Discovery agent N.A. Investigative [96]
5,6-Bis-p-tolylamino-isoindole-1,3-dione DM6A4LM Discovery agent N.A. Investigative [80]
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide DMB7R95 Discovery agent N.A. Investigative [94]
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline DMI7FVJ Discovery agent N.A. Investigative [95]
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline DMFVT8A Discovery agent N.A. Investigative [95]
6,7-diethoxy-4-styrylquinazoline DMVR4OW Discovery agent N.A. Investigative [95]
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline DMQTHV7 Discovery agent N.A. Investigative [95]
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline DMKO8QT Discovery agent N.A. Investigative [95]
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline DMBI40Y Discovery agent N.A. Investigative [95]
6,7-dimethoxy-N-m-tolylquinazolin-4-amine DMP8LXB Discovery agent N.A. Investigative [97]
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine DMPIFLA Discovery agent N.A. Investigative [98]
AFM-21 DM8U1IW Solid tumour/cancer 2A00-2F9Z Investigative [5]
AG 112 DMDYS0L Discovery agent N.A. Investigative [99]
AG 9 DMSOUI0 Discovery agent N.A. Investigative [99]
AG-213 DMT3ML6 Discovery agent N.A. Investigative [93]
AG-538 DM9KIS8 Discovery agent N.A. Investigative [86]
AGT-2000 DMP9QW0 Brain cancer 2A00 Investigative [5]
AL-6802 DM3JNRC Solid tumour/cancer 2A00-2F9Z Investigative [5]
Anti-EGFR humanized mabs DMWLMV2 Solid tumour/cancer 2A00-2F9Z Investigative [5]
Anti-EGFR mab DMW85FP Discovery agent N.A. Investigative [5]
ARX-AHD DM15KLR Breast cancer 2C60-2C65 Investigative [5]
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine DMISHTB Discovery agent N.A. Investigative [84]
Benzyl-quinazolin-4-yl-amine DMRW5J4 Discovery agent N.A. Investigative [83]
Bmab-200 DM8AEQX Solid tumour/cancer 2A00-2F9Z Investigative [5]
BPIQ-I DMNHEUT Discovery agent N.A. Investigative [84]
CL-387785 DMLKFZC Discovery agent N.A. Investigative [97]
Cochliobolic acid DMOUSWN Discovery agent N.A. Investigative [100]
EDP-13 DMLSMBI Solid tumour/cancer 2A00-2F9Z Investigative [5]
EGFR inhibitor DM7AYH4 Discovery agent N.A. Investigative [101]
Epitinib DM1C8FW Solid tumour/cancer 2A00-2F9Z Investigative [5]
FHT-2107 DMH7LDX Discovery agent N.A. Investigative [5]
GI-3000 DMU92RC Non-small-cell lung cancer 2C25.Y Investigative [5]
HDS-029 DMLRUVA Discovery agent N.A. Investigative [102]
HKI-9924129 DM5LR2B Gram-positive bacterial infection 1B74-1G40 Investigative [103]
HM-61713B DMNOFTX Solid tumour/cancer 2A00-2F9Z Investigative [5]
HTS-00213 DMQ8ADE Discovery agent N.A. Investigative [97]
HTS-02876 DMVUTJ5 Discovery agent N.A. Investigative [97]
HTS-05058 DM3F4IQ Discovery agent N.A. Investigative [101]
ICR 62 DMH4KGX Discovery agent N.A. Investigative [33]
IPS-01003 DM0T8ZU Solid tumour/cancer 2A00-2F9Z Investigative [5]
LA22-radioimmunoconjugates DMY6K2A Solid tumour/cancer 2A00-2F9Z Investigative [5]
LAVENDUSTIN A DMH3X06 Discovery agent N.A. Investigative [104]
mabionHER2 DMJX2CS Breast cancer 2C60-2C65 Investigative [5]
MDP-01 DM8ZK12 Solid tumour/cancer 2A00-2F9Z Investigative [5]
MG-111 DMG56EU Discovery agent N.A. Investigative [105]
MT-062 DM5PD0G Melanoma 2C30 Investigative [5]
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine DMFWN5U Discovery agent N.A. Investigative [84]
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine DMUI8RC Discovery agent N.A. Investigative [106]
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine DMO56XY Discovery agent N.A. Investigative [83]
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine DMK674I Discovery agent N.A. Investigative [107]
N-(4-(phenylamino)quinazolin-6-yl)acrylamide DMI74KM N. A. N. A. Investigative [108]
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide DMEBGF1 Discovery agent N.A. Investigative [109]
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide DMG6RTJ Discovery agent N.A. Investigative [109]
N4-(3-chlorophenyl)quinazoline-4,6-diamine DM561Z7 Discovery agent N.A. Investigative [110]
N4-(3-methylphenyl)-4,6-quinazolinediamine DMDRYJ7 Discovery agent N.A. Investigative [111]
NRC-2694 DMXP03H Solid tumour/cancer 2A00-2F9Z Investigative [5]
ON-128 DMTNKBW Solid tumour/cancer 2A00-2F9Z Investigative [5]
OSI-75 DM5IGN7 Discovery agent N.A. Investigative [112]
PD-0166326 DMD2CG9 Discovery agent N.A. Investigative [103]
PD-0173956 DM8RW92 Discovery agent N.A. Investigative [103]
PD-158780 DMQXYE9 Discovery agent N.A. Investigative [107]
PD-168393 DMN8M5P Discovery agent N.A. Investigative [108]
PD182905 DMXLW4F Discovery agent N.A. Investigative [113]
PF 5208766 DMY45K1 Discovery agent N.A. Investigative [114]
PMID24915291C38 DMBXT9J Discovery agent N.A. Investigative [115]
PMID8568816C56 DMG3ZD1 Discovery agent N.A. Investigative [116]
PP121 DMU8KTO Discovery agent N.A. Investigative [117]
RG-50810 DMUR9LM Discovery agent N.A. Investigative [86]
RM-6427 DM87Z3Y Cryptosporidium infection 1A32 Investigative [5]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [118]
RX-1792 DMKYNGE Solid tumour/cancer 2A00-2F9Z Investigative [5]
SYM-011 DMKIDRY Solid tumour/cancer 2A00-2F9Z Investigative [5]
TGF alpha DMOX3AH Cerebrovascular ischaemia 8B1Z Investigative [5]
Theliatinib DMRVXFN Solid tumour/cancer 2A00-2F9Z Investigative [5]
Tyrphostin Ag-1478 DM87ZIH Discovery agent N.A. Investigative [90]
WHI-P154 DMYHWS1 Diffuse large B-cell lymphoma 2A81 Investigative [119]
WZ-3146 DMBWUR0 Lung cancer 2C25.0 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 103 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Head and neck cancer 2C82 Head and neck tissue 5.84E-05 0.32 0.55
Neuroectodermal tumour 2C82 Nervous tissue 8.30E-26 0.06 0.13
Breast cancer 2C82 Breast tissue 1.04E-65 -0.89 -1.53
Lung cancer 2C82 Lung tissue 1.65E-01 -0.04 -0.09
Glioma 2C82 Brainstem tissue 2.09E-05 0.4 190.08
Glioma 2C82 White matter 6.32E-04 0.39 1.69
Prostate cancer 2C82 Prostate 7.43E-04 -0.59 -0.82
Ovarian cancer 2C82 Ovarian tissue 9.25E-01 -0.01 -0.03
Bladder cancer 2C82 Bladder tissue 5.87E-01 0.09 0.29
Rectal cancer 2C82 Rectal colon tissue 1.07E-02 -0.25 -1.63
Melanoma 2C82 Skin 1.60E-01 -0.34 -0.23
Psoriasis EA90 Skin 1.86E-07 -0.27 -0.42
Gastric cancer 2C82 Gastric tissue 2.52E-01 -0.42 -2.17
Ureter cancer 2C82 Urothelium 5.34E-01 -0.07 -0.71
------------------------------------------------------------------------------------
⏷ Show the Full List of DTT Expression Under 14 Diseases

References

1 Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
2 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
3 Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7.
4 Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
6 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
7 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
8 Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40.
9 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
10 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
11 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
12 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
13 Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
14 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
15 AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
16 Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
17 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
18 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
19 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
20 Clinical pipeline report, company report or official report of AstraZeneca (2009).
21 Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.
22 Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918.
23 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
24 ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
25 Clinical pipeline report, company report or official report of Roche (2009).
26 Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
27 Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.
28 Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
29 Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.
30 Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
31 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
32 Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
33 Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
34 Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
35 AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61.
36 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
37 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
38 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
39 Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
40 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
41 Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
42 Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.
43 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
44 EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.
45 Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
46 BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
47 Clinical pipeline report, company report or official report of Affimed Therapeutics.
48 Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
49 ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
50 ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
51 Clinical pipeline report, company report or official report of EpimAb Biotherapeutics.
52 Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
53 Clinical pipeline report, company report or official report of Shionogi (2011).
54 AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.
55 ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
56 Company report (Biooncology)
57 AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.
58 Development and validation of a sensitive LC-MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma.J Pharm Biomed Anal.2013 Dec;86:49-55.
59 Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation.Drug Metab Dispos.2014 May;42(5):872-84.
60 ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
61 Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
62 TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
63 A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
64 Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
65 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
66 World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
67 National Cancer Institute Drug Dictionary (drug id 596693).
68 Clinical pipeline report, company report or official report of Merus.
69 A Phase I Study of Immunotoxin, MR1-1. Duke University report.
70 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
71 Clinical pipeline report, company report or official report of SystImmune.
72 Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
73 Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403.
74 GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38.
75 EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9.
76 A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11.
77 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
78 WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
79 Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.
80 Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.
81 The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.
82 Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994 Aug 5;269(31):20060-6.
83 Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
84 Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
85 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9.
86 Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
87 Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
88 Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
89 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
90 Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
91 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
92 A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
93 Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
94 Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
95 Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
96 Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
97 Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
98 Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
99 Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.
100 Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8.
101 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
102 Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
103 Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
104 Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84.
105 Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201.
106 Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51.
107 Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
108 Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
109 Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
110 Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8.
111 The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52.
112 Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
113 Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22.
114 Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
115 Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
116 Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
117 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
118 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
119 The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.